Company

SwanBio Therapeutics, Inc.

SwanBio Therapeutics develops gene therapies for rare genetic diseases, including Gaucher disease and Parkinson's disease.

About

Founded in 2018 in the US, SwanBio Therapeutics, Inc. develops gene therapies for rare genetic diseases, including Gaucher disease, Parkinson's disease and some forms of dementia. Its SBT101 program is in clinical development, and the company targets hospitals and specialized providers in North America and Europe. It raised USD 56.00 mn in Series B funding on May 18, 2022, with participation from Mass General Brigham Ventures and Syncona Limited. It has completed three known deals.

3Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in